We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the first head-to-head comparison between two commonly used HIV treatments, researchers found one triple-drug therapy was significantly more effective at reducing HIV viral load in the blood when used as a first-line treatment.
ViRexx Medical has announced that enrolment and treatment has been completed in the Phase I trial of its HepaVaxx B Vaccine, the lead candidate from the company's Chimigen vaccine platform.
Anacor Pharmaceuticals announced that a Phase I trial of its compound AN2690 showed that patients receiving the topical treatment had no measurable level of the drug in their bloodstream.
RegeneRx Biopharmaceuticals has received a $545,000 grant from the FDA's Office of Orphan Products Development for the development of its drug candidate based on Thymosin beta 4 (TB4).
Human Genome Sciences (HGS) announced the start of its Phase III clinical development program for LymphoStat-B (belimumab) in patients with active systemic lupus erythematosus.
Join FDAnews Thursday, Aug. 17, for "Data Monitoring Committees: Strategies for Future Trial Design." In this 90-minute interactive audioconference, healthcare attorney Clint Hermes, Ropes & Gray, New York, outlines the biggest challenges in the new FDA DMC guidance and provides solutions to help prevent issues that could attract FDA scrutiny. On Aug. 30, join FDAnews for "Reduce FDA Restrictions on Scheduled Products: How to Develop Effective RiskMAPs as Part of the NDA." In this 90-minute audioconference with Q&A session, Edgar Adams, Sc.D., executive director of epidemiology, Late Stage Development Services Unit, Covance, helps you discover how to apply "worst case" scenarios so that you can significantly reduce risks for your scheduled products.